Gore’s Cardioform ASD Occluder Approved and Launched in Europe
October 2, 2019—Gore & Associates announced CE Mark approval and the European launch of the Cardioform atrial septal defect (ASD) occluder for percutaneous transcatheter closure of ostium secundum ASDs.
According to Gore, the Cardioform ASD occluder’s anatomically adaptable waist conforms to the defect to close ASDs with diameters of 8 to 35 mm, including those without a retroaortic rim, by facilitating optimal tissue ingrowth while maintaining thromboresistance. The ability to retrieve and reposition the device helps ensure proper positioning and offers physicians confident closure.
The recent ASSURED clinical study evaluated the safety and efficacy of ASD closure using the Cardioform device in 125 patients with evidence of right heart volume overload demonstrating the need for defect closure. The study included patients between the ages of 2 and 84, across 22 investigation sites, including 15 children’s hospitals. The pivotal study met its safety, closure, and technical success primary endpoints.
In June 2019, Gore announced that the Cardioform ASD occluder received premarket approval from the FDA for treatment of ASDs in the United States.
Matthew Gillespie, MD, Coprincipal Investigator of the ASSURED clinical study, commented in Gore’s announcement, “Larger defects typically have a greater risk for complications, like pulmonary hypertension, right heart enlargement, or atrial fibrillation. But previously, Europe didn’t have access to the Gore Cardioform ASD occluder for this range of defects. CE Mark makes this soft, conformable device available for the minimally invasive treatment of a broader range of ASDs.” Dr. Gillespie is from Children’s Hospital of Philadelphia in Philadelphia, Pennsylvania.
Sponsored by Cardiovascular Systems Inc.
Top 5 Articles From August 2019
State-of-the-art closure techniques for large-bore access.
By Amir Kaki, MD; and M. Chadi Alraies, MD
Mastering the ultrasound-guided access technique for cardiac and noncardiac interventions can reduce access-related complications and improve outcomes.
By Maarten P. van Wiechen, MD; and Nicolas M. Van Mieghem, MD, PhD, FACC, FESC
A guide to understanding intracardiac echocardiography for PFO closure, including available technologies, proper techniques, and potential benefits and limitations.
By Mohamad Alkhouli, MD
An overview of innovative preprocedural and intraprocedural imaging techniques, trial data, and current LAAO devices and devices in development.
By Saurabh Sanon, MD; and D. Scott Lim, MD
Discussing the design and function of radial artery compression technologies used for a safe closure of radial access after percutaneous cardiovascular intervention.
By Francesco Costa, MD, PhD, FESC; and Renato Scalise, MD
Top 5 from EVToday's Current Issue
Technical and procedural innovations in Y-90 radioembolization including existing and investigational next-generation technologies.
By Robert Abraham, MD, FRCPC, FSIR; Robert Lewandowski, MD, FSIR; Ripal T. Gandhi, MD, FSIR, FSVM; and David M. Liu, MD, FRCPC, FSIR
Considerations for choosing the right access equipment.
By Darren Klass, MBChB, MD, MRCS, FCRC, FRCPC; Anastasia Hadjivassiliou, MBBS, FRCR, FRCPC; and John Chung, MD, FRCPC
Clinical and technical insights into treating hepatocellular carcinoma, cholangiocarcinoma, renal cell carcinoma, lung cancer, bone cancer, and in the palliative care setting.
By Siddharth A. Padia, MD; Theodore Bryan, MD; Rebecca Bennett, MD; Nadine Abi-Jaoudeh, MD, FSIR, CCRP; Raul N. Uppot, MD; Robert Suh, MD; Paul I. Mallinson, MBChB, FRCR, FRCPC; Peter L. Munk, MDCM, FRCPC, FSIR, FFRRCSI (Hon); Miyuki Sone, MD; and Yasuaki Arai, MD, FSIR, FCIRSE
An update on state-of-the-art minimally invasive therapies, including recent advances in surgery, radiation therapy, ablative options, and endovascular therapies.
By Ripal T. Gandhi, MD, FSIR, FSVM; Horacio Asbun, MD; Michael Chuong, MD; Filipe Kunzler, MD; and Govindarajan Narayanan, MD
Cases highlighting the potential for early benefit and improved quality of life and function associated with the use of FlowTriever and ClotTriever Systems in patients with cancer and VTE.
With Sirish A. Kishore, MD; and William C. Dillon, MD, FACC